490 related articles for article (PubMed ID: 25856302)
21. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
22. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
24. Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery.
Kuang Y; Jiang X; Zhang Y; Lu Y; Ma H; Guo Y; Zhang Y; An S; Li J; Liu L; Wu Y; Liang J; Jiang C
Mol Pharm; 2016 May; 13(5):1599-607. PubMed ID: 27058780
[TBL] [Abstract][Full Text] [Related]
25. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy.
Pang L; Zhu Y; Qin J; Zhao W; Wang J
Drug Deliv; 2018 Nov; 25(1):1922-1931. PubMed ID: 30465444
[TBL] [Abstract][Full Text] [Related]
26. Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma.
Householder KT; DiPerna DM; Chung EP; Wohlleb GM; Dhruv HD; Berens ME; Sirianni RW
Int J Pharm; 2015 Feb; 479(2):374-80. PubMed ID: 25562639
[TBL] [Abstract][Full Text] [Related]
27. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles.
Ruan S; Yuan M; Zhang L; Hu G; Chen J; Cun X; Zhang Q; Yang Y; He Q; Gao H
Biomaterials; 2015 Jan; 37():425-35. PubMed ID: 25453970
[TBL] [Abstract][Full Text] [Related]
28. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles.
Wei L; Guo XY; Yang T; Yu MZ; Chen DW; Wang JC
Int J Pharm; 2016 Aug; 510(1):394-405. PubMed ID: 27374198
[TBL] [Abstract][Full Text] [Related]
29. Mn
Xi J; Da L; Yang C; Chen R; Gao L; Fan L; Han J
Int J Nanomedicine; 2017; 12():3331-3345. PubMed ID: 28479854
[TBL] [Abstract][Full Text] [Related]
30. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
31. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.
Su WP; Cheng FY; Shieh DB; Yeh CS; Su WC
Int J Nanomedicine; 2012; 7():4269-83. PubMed ID: 22904633
[TBL] [Abstract][Full Text] [Related]
32. Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier - from Targeting to Safe Administration.
Gomes MJ; Fernandes C; Martins S; Borges F; Sarmento B
J Neuroimmune Pharmacol; 2017 Mar; 12(1):107-119. PubMed ID: 27209050
[TBL] [Abstract][Full Text] [Related]
33. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.
Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S
Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558
[TBL] [Abstract][Full Text] [Related]
34. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Kim TH; Jeong YI; Jin SG; Pei J; Jung TY; Moon KS; Kim IY; Kang SS; Jung S
Int J Nanomedicine; 2011; 6():2621-31. PubMed ID: 22114493
[TBL] [Abstract][Full Text] [Related]
35. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas.
Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y
Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677
[TBL] [Abstract][Full Text] [Related]
36. Multifunctional Polyethylene Glycol (PEG)-Poly (Lactic-Co-Glycolic Acid) (PLGA)-Based Nanoparticles Loading Doxorubicin and Tetrahydrocurcumin for Combined Chemoradiotherapy of Glioma.
Zhang X; Zhao L; Zhai G; Ji J; Liu A
Med Sci Monit; 2019 Dec; 25():9737-9751. PubMed ID: 31856143
[TBL] [Abstract][Full Text] [Related]
37. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers.
Geldenhuys W; Wehrung D; Groshev A; Hirani A; Sutariya V
Pharm Dev Technol; 2015 Jun; 20(4):497-506. PubMed ID: 24597667
[TBL] [Abstract][Full Text] [Related]
38. Co-delivery of Doxorubicin Encapsulated PLGA Nanoparticles and Bcl-xL shRNA Using Alkyl-Modified PEI into Breast Cancer Cells.
Ebrahimian M; Taghavi S; Mokhtarzadeh A; Ramezani M; Hashemi M
Appl Biochem Biotechnol; 2017 Sep; 183(1):126-136. PubMed ID: 28236188
[TBL] [Abstract][Full Text] [Related]
39. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.
Yang ZZ; Li JQ; Wang ZZ; Dong DW; Qi XR
Biomaterials; 2014 Jun; 35(19):5226-39. PubMed ID: 24695093
[TBL] [Abstract][Full Text] [Related]
40. Na
Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M
Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
